Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) has a cash flow conversion efficiency ratio of -0.053x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-507.58K) by net assets ($9.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see HKPD stock market capitalisation for the company's overall valuation and market capitalisation.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares - Cash Flow Conversion Efficiency Trend (2023–2026)
This chart illustrates how Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares ranked by their cash flow conversion efficiency. Explore HKPD cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gibb River Diamonds Ltd
AU:GIB
|
-1.410x |
|
Bri-Chem Corp.
TO:BRY
|
0.008x |
|
Comperia.pl S.A.
WAR:CPL
|
0.078x |
|
Bladeranger Ltd
TA:BLRN
|
-0.058x |
|
Celtic plc
LSE:CCPC
|
-0.038x |
|
Willow Biosciences Inc
TO:WLLW
|
0.055x |
|
THOR MNG CUFS/1LS- 00001
F:T5MB
|
N/A |
|
Agroz Inc. Ordinary Shares
NASDAQ:AGRZ
|
N/A |
Annual Cash Flow Conversion Efficiency for Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (2023–2026)
The table below shows the annual cash flow conversion efficiency of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares from 2023 to 2026. View latest Hong Kong Pharma Digital Technology Hold stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $9.58 Million | $-751.60K | -0.078x | -168.75% |
| 2025-03-31 | $4.99 Million | $569.21K | 0.114x | +223.05% |
| 2024-03-31 | $4.25 Million | $-394.33K | -0.093x | -103.14% |
| 2023-03-31 | $585.24K | $1.73 Million | 2.951x | -- |
About Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides valu… Read more